Identification of synergistic drug combinations using breast cancer patient-derived xenografts
出版年份 2020 全文链接
标题
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
作者
关键词
-
出版物
Scientific Reports
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-01-30
DOI
10.1038/s41598-020-58438-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer
- (2018) Tia H. Turner et al. BREAST CANCER RESEARCH AND TREATMENT
- Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
- (2018) Alice Lee et al. CANCER TREATMENT REVIEWS
- EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer
- (2018) Chun-Chia Cheng et al. LUNG CANCER
- YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction
- (2018) Chun-Hua Dai et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
- (2018) Wenhao Zhang et al. PROSTATE
- YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells
- (2017) Chun-Chia Cheng et al. PLoS One
- Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
- (2017) Kuan-lin Huang et al. Nature Communications
- Triple negative breast cancer: the kiss of death
- (2017) Adriana-Andreea Jitariu et al. Oncotarget
- Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
- (2017) Branka Radic-Sarikas et al. Scientific Reports
- A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer
- (2017) Paul Savage et al. Cell Reports
- YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells
- (2017) Xiang Yan et al. MEDICAL SCIENCE MONITOR
- Loss of SLCO1B3 drives taxane resistance in prostate cancer
- (2016) Ellen S de Morrée et al. BRITISH JOURNAL OF CANCER
- A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
- (2016) Alejandra Bruna et al. CELL
- Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
- (2016) Abderrahim El Guerrab et al. Oncotarget
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer
- (2016) Yoon Young Choi et al. Scientific Reports
- Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer
- (2015) A. Mehta et al. CLINICAL CANCER RESEARCH
- Survivin: A molecular biomarker in cancer
- (2015) RD Mittal et al. INDIAN JOURNAL OF MEDICAL RESEARCH
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening
- (2015) Maria A. Theodoraki et al. Oncotarget
- YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
- (2015) Eloïse Véquaud et al. Oncotarget
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Survivin and YM155: How faithful is the liaison?
- (2014) Anke Rauch et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Three-dimensional in vitro tumor models for cancer research and drug evaluation
- (2014) Xian Xu et al. BIOTECHNOLOGY ADVANCES
- Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
- (2014) Michael R. Clemens et al. BREAST CANCER RESEARCH AND TREATMENT
- YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells
- (2014) S M Cheng et al. BRITISH JOURNAL OF PHARMACOLOGY
- Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma
- (2014) X. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma
- (2013) Yu-Fan Wang et al. APOPTOSIS
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
- (2013) Rachel M. Layman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
- (2013) X. Zhang et al. CANCER RESEARCH
- Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
- (2013) D. Siolas et al. CANCER RESEARCH
- Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
- (2013) Yong Weon Yi et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Deconstructing the third dimension – how 3D culture microenvironments alter cellular cues
- (2012) Brendon M. Baker et al. JOURNAL OF CELL SCIENCE
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
- (2012) Young-Soon Na et al. PLoS One
- Targeting EGFR in Triple Negative Breast Cancer
- (2012) Naoto T. Ueno et al. Journal of Cancer
- Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
- (2011) J. Chuck Harrell et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin
- (2011) K. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
- (2011) Yoko S DeRose et al. NATURE MEDICINE
- Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: Comparison of the CGH profiles between cancer cell lines and primary cancer tissues
- (2010) Katumi Tsuji et al. BMC CANCER
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Deconstructing the molecular portraits of breast cancer
- (2010) Aleix Prat et al. Molecular Oncology
- Genome remodelling in a basal-like breast cancer metastasis and xenograft
- (2010) Li Ding et al. NATURE
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals
- (2009) Xiang H.-F. Zhang et al. CANCER CELL
- An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine
- (2009) M-D Lai et al. CANCER GENE THERAPY
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Genes that mediate breast cancer metastasis to the brain
- (2009) Paula D. Bos et al. NATURE
- Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer
- (2008) W M van Weerden et al. BRITISH JOURNAL OF CANCER
- Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
- (2008) I. Fichtner et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started